Matsuda Kiku, Chaudhari Atul A, Lee John Hwa
College of Veterinary Medicine, Chonbuk National University, Jeonju 561-756, Republic of Korea.
Avian Dis. 2011 Sep;55(3):407-12. doi: 10.1637/9680-020611-Reg.1.
We evaluated a recently developed live vaccine candidate for fowl typhoid (FT)-JOL916, a lon/cpxR mutant of Salmonella Gallinarum (SG)-by comparing its safety and efficacy with that of the well-known rough mutant strain SG9R vaccine in 6-wk-old Hy-Line hens. Forty-five chickens were divided into three groups of 15 chickens each. The chickens were then intramuscularly inoculated with 2 x 10(7) colony-forming units (CFUs) of JOL916 (JOL916 group), 2 x 10(7) CFUs of SG9R (SG9R group), or phosphate-buffered saline (control group). After vaccination, no clinical symptoms were observed in any of the groups. No differences in body weight increase were detected among the three groups postvaccination. A cellular immune response was observed at 2 wk postvaccination (wpv) in the JOL916 group with the peripheral lymphocyte proliferation assay, whereas no response was detected in the SG9R group. Elevation of SG antigen-specific plasma immunoglobulin was observed 2 and 3 wpv in the JOL916 and SG9R vaccine groups, respectively. After virulent challenge on day 25 postvaccination, 0, 1, and 15 chickens in the JOL916 group, SG9R group, and control group, respectively, died by 12 days postchallenge; the death rate of the SG9R vaccine group was statistically similar to that of the JOL916 group. Postmortem examination revealed that the JOL916 vaccine offered more efficient protection than the SG9R vaccine, with significantly decreased hepatic necrotic foci scores, splenic enlargement scores, necrotic foci scores, and recovery of the challenge strain from the spleen. Vaccination with JOL916 appears to be safe and offers better protection than SG9R against FT in chickens.
我们通过在6周龄的海兰母鸡中比较其与著名的粗糙突变株SG9R疫苗的安全性和有效性，评估了一种最近开发的用于禽伤寒（FT）的活疫苗候选株——鸡沙门氏菌（SG）的lon/cpxR突变株JOL916。45只鸡被分成三组，每组15只。然后给鸡肌肉注射2×10⁷菌落形成单位（CFU）的JOL916（JOL916组）、2×10⁷CFU的SG9R（SG9R组）或磷酸盐缓冲盐水（对照组）。接种疫苗后，任何一组均未观察到临床症状。接种疫苗后，三组之间未检测到体重增加的差异。接种疫苗后2周（wpv），通过外周淋巴细胞增殖试验在JOL916组观察到细胞免疫反应，而在SG9R组未检测到反应。在接种疫苗后2周和3周，分别在JOL916和SG9R疫苗组观察到SG抗原特异性血浆免疫球蛋白升高。在接种疫苗后第25天进行强毒攻击后，到攻击后12天，JOL916组、SG9R组和对照组分别有0只、1只和15只鸡死亡；SG9R疫苗组的死亡率与JOL916组在统计学上相似。尸检显示，JOL916疫苗比SG9R疫苗提供了更有效的保护，肝坏死灶评分、脾肿大评分、坏死灶评分显著降低，且从脾脏中回收的攻击菌株减少。接种JOL916疫苗似乎是安全的，并且在鸡中对禽伤寒的保护作用比SG9R更好。
